Possible nephrotoxic effects of high dose statin therapy; current knowledge

Q3 Medicine
Fariba Ahmadiazar, Mehrdad Rahmanian, Zahra Jalali, Akshaya Joseph, M. Foroutan
{"title":"Possible nephrotoxic effects of high dose statin therapy; current knowledge","authors":"Fariba Ahmadiazar, Mehrdad Rahmanian, Zahra Jalali, Akshaya Joseph, M. Foroutan","doi":"10.34172/npj.2022.10574","DOIUrl":null,"url":null,"abstract":"Introduction The 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) inhibitors (i.e., statins) are recommended as a first-line of cholesterol-lowering medication for lipid control. Statins reduce low-density lipoprotein cholesterol (LDL-c), a chief contributor to atherosclerotic cardiovascular disease, which helps prevent cardiovascular disease. Recent studies demonstrate that high-dose statins augment LDL-c reduction and lead to improving cardiovascular outcomes compared to lowor moderatedose statin therapy in atherosclerotic cardiovascular disease patients (1). The benefits of high-dose statin therapy on cardiovascular risks have increased prescribing of high-dose statins. Despite beneficial effects with statin therapy, treatment with these agent is also associated with adverse events. These adverse effects range from nonthreatening asymptomatic presentations to severe organ dysfunction, especially of the kidneys and liver. Severe adverse effects associated with statin treatment include muscle damage, renal failure, liver dysfunction and polyneuropathy. Specific side effects of renal origin include rhabdomyolysis, proteinuria and acute kidney injury (AKI). Acute kidney injury Several clinical studies propose that high-dose statin treatment will increase the risk of AKI. However, cardiovascular surgery patients may respond differently to the type and dose of statin therapy. For instance, highdose statins are associated with a high risk of AKI in patients of the general population. In contrast, equivalent doses of those statins in cardiovascular surgery patients demonstrated renoprotective effects (2). Numerous studies suggest that high-dose statins will significantly increase the risk of contrast-induced AKI. A previous study has demonstrated a relationship between the high dose of atorvastatin and renal injury if administered alone or in combination with high doses of garlic; while a low-dose of atorvastatin in combination with high doses of garlic has negligible nephrotoxic effects (3). Statins should be administered cautiously in coronary artery disease patients undergoing coronary angiography (3,4). Hospitalization due to AKI was 34% higher in the cohort that received high-dose statin therapy compared to the cohort that administered low-dose statin therapy (2). High doses of atorvastatin have nephrotoxic effects, while lower doses have beneficial effects on renal function and structure (2) suggesting that, high doses of statins may be Ep id em io lo gy a nd P re ve nt io n","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nephropharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/npj.2022.10574","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction The 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) inhibitors (i.e., statins) are recommended as a first-line of cholesterol-lowering medication for lipid control. Statins reduce low-density lipoprotein cholesterol (LDL-c), a chief contributor to atherosclerotic cardiovascular disease, which helps prevent cardiovascular disease. Recent studies demonstrate that high-dose statins augment LDL-c reduction and lead to improving cardiovascular outcomes compared to lowor moderatedose statin therapy in atherosclerotic cardiovascular disease patients (1). The benefits of high-dose statin therapy on cardiovascular risks have increased prescribing of high-dose statins. Despite beneficial effects with statin therapy, treatment with these agent is also associated with adverse events. These adverse effects range from nonthreatening asymptomatic presentations to severe organ dysfunction, especially of the kidneys and liver. Severe adverse effects associated with statin treatment include muscle damage, renal failure, liver dysfunction and polyneuropathy. Specific side effects of renal origin include rhabdomyolysis, proteinuria and acute kidney injury (AKI). Acute kidney injury Several clinical studies propose that high-dose statin treatment will increase the risk of AKI. However, cardiovascular surgery patients may respond differently to the type and dose of statin therapy. For instance, highdose statins are associated with a high risk of AKI in patients of the general population. In contrast, equivalent doses of those statins in cardiovascular surgery patients demonstrated renoprotective effects (2). Numerous studies suggest that high-dose statins will significantly increase the risk of contrast-induced AKI. A previous study has demonstrated a relationship between the high dose of atorvastatin and renal injury if administered alone or in combination with high doses of garlic; while a low-dose of atorvastatin in combination with high doses of garlic has negligible nephrotoxic effects (3). Statins should be administered cautiously in coronary artery disease patients undergoing coronary angiography (3,4). Hospitalization due to AKI was 34% higher in the cohort that received high-dose statin therapy compared to the cohort that administered low-dose statin therapy (2). High doses of atorvastatin have nephrotoxic effects, while lower doses have beneficial effects on renal function and structure (2) suggesting that, high doses of statins may be Ep id em io lo gy a nd P re ve nt io n
高剂量他汀类药物治疗可能的肾毒性作用;当前知识
3-羟基-3-甲基戊二酰辅酶A还原酶(HMG-CoA还原酶)抑制剂(即他汀类药物)被推荐作为控制血脂的一线降胆固醇药物。他汀类药物降低低密度脂蛋白胆固醇(LDL-c),这是动脉粥样硬化性心血管疾病的主要原因,有助于预防心血管疾病。最近的研究表明,在动脉粥样硬化性心血管疾病患者中,与中低剂量他汀类药物治疗相比,高剂量他汀类药物可增强LDL-c的降低,改善心血管预后(1)。高剂量他汀类药物治疗对心血管风险的益处增加了高剂量他汀类药物的处方。尽管他汀类药物治疗有有益的效果,但这些药物的治疗也与不良事件有关。这些不良反应的范围从无威胁的无症状表现到严重的器官功能障碍,特别是肾脏和肝脏。与他汀类药物治疗相关的严重不良反应包括肌肉损伤、肾功能衰竭、肝功能障碍和多发性神经病变。肾源性的特殊副作用包括横纹肌溶解、蛋白尿和急性肾损伤(AKI)。一些临床研究表明,大剂量他汀类药物治疗会增加AKI的风险。然而,心血管手术患者可能对他汀类药物治疗的类型和剂量有不同的反应。例如,在普通人群中,高剂量他汀类药物与AKI的高风险相关。相反,同等剂量的他汀类药物在心血管手术患者中显示出肾脏保护作用(2)。大量研究表明,高剂量他汀类药物会显著增加造影剂诱导AKI的风险。先前的一项研究表明,如果单独使用或与高剂量大蒜联合使用,高剂量阿托伐他汀与肾损伤之间存在关系;而低剂量阿托伐他汀联合高剂量大蒜的肾毒性作用可以忽略不计(3)。接受冠状动脉造影的冠状动脉疾病患者应谨慎使用他汀类药物(3,4)。与接受低剂量他汀治疗的队列相比,接受高剂量他汀治疗的队列因AKI住院率高出34%(2)。高剂量阿托伐他汀有肾毒性作用,而低剂量他汀对肾功能和肾脏结构有有益作用(2),这表明,高剂量他汀可能对肾功能和肾结构有保护作用
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Nephropharmacology
Journal of Nephropharmacology Medicine-Pharmacology (medical)
CiteScore
1.70
自引率
0.00%
发文量
18
审稿时长
4 weeks
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信